Healthcare
Cannabis Users are Less Likely to Get Liver Cancer Says New Medical Study
Liver cancer is one of the fastest-growing cancers. Once you have it, liver cancer is a life-threatening condition and it can quickly turn fatal.
Primary liver cancer begins in the organ itself, while secondary cancer means that it has spread to the liver from another part of the body. Among the three kinds of primary liver cancer, hepatocellular carcinoma (HCC) is the most common form, followed by intrahepatic cancer then angiosarcoma. Liver cancer can be caused by several factors including fatty liver disease, diabetes, alcoholism, tobacco smoking, obesity, and toxic chemical exposure.
Though liver cancer mostly affects seniors aged 55 to 65, anyone can get liver cancer. The prognosis is 3 to 35, according to Cancer.org, depending on how far the cancer has progressed once it has been diagnosed.
However, new studies have shown that cannabis consumers are less likely to get liver cancer.
New data that has been published in Cureus, a medical journal, revealed that adults who have a recent history of marijuana consumption are twice less likely to develop hepatocellular carcinoma compared to those who don’t have a history of cannabis use. To come up with these findings, researchers from Cleveland Clinic together with investigators at the Georgetown University Hospital in Washington DC analyzed more than 1 million subjects as well as their cannabis consumption patterns and the prevalence of hepatocellular carcinoma among them.
They reported that current marijuana consumers are “55 percent less likely to have HCC compared to non-cannabis users.”
“To the best of our knowledge, this is the first and largest population-based cross-sectional study of hospitalized patients to explore the association between cannabis use and HCC…. Due to the cross-sectional structure of our study, we are unable to draw direct causation effects. Hence, we suggest prospective clinical studies to further understand the mechanism by which various active ingredients, particularly CBD in cannabis, may possibly regulate hepatocellular carcinoma development,” the authors concluded.
Other Studies
There have been other studies that echo these findings.
In 2018, a study analyzed around 320,000 participants all of whom had a history of alcohol abuse as well as marijuana. The researchers wanted to see if there was any correlation between alcohol and drugs on liver health. According to Dr. Terence Bukong, one of the study’s researchers: “The primary aim of our study was to assess the impact of cannabis use and the development of alcoholic liver disease,” he tells Healthline. “Given that no clinical studies had previously evaluated the impact of cannabis use and the development of progressive stages of alcoholic liver disease in humans, we thought that this was an important research area which needed urgent investigation,” he says.
Meanwhile, a study out of the Hebrew University of Jerusalem discovered a way of treating liver cancer patients with chemotherapy straight into the affected cells while keeping the healthy cells intact. The method makes use of CBD together with a low dose of doxorubicin, a medicine commonly used in chemotherapy.
“Most anticancer treatments are not sufficiently specific, meaning they attack healthy cells together with the malignant ones they’re trying to get rid of,” says Prof. Alexander Binshtok, the Hebrew University’s Faculty of Medicine and Edmond & Lily Safra Center for Brain Sciences head for Pain Plasticity Research. “This leads to many serious side effects associated with chemotherapy. Eliminating cancerous cells while leaving healthy ones alone is an important step toward reducing patients’ suffering,” he adds.
Doxorubicin works for the cancerous cells, though it also has negative side effects for liver and heart cells, which can even cause heart failure when used for liver cancer treatment, Binshtok told The Jerusalem Post.
Another study from 2020 shared similar findings – that cannabis users are generally less likely to contract cancer, compared to non-users.
A meta review conducted by Indiana University South Bend Departmental Chair & Professor of Biology, Dr. Thomas M. Clark, involved 34 varying research studies on marijuana and cancer. Using a statistical analysis, he was able to discover that cannabis users are generally healthier and had a smaller chance of getting cancer.
“The impact of cannabis use on cancer risk is of considerable interest,” Clark said. “Cancer is a leading cause of death in the United States and around the world. In the United States alone, >1.7 million diagnoses and 607,000 deaths are projected from cancer in 2019…. And cancer deaths were responsible for $94.4 billion in lost earnings in 2015,” he says.
The statistical analysis took all kinds of cancer into account, and they ended up concluding that cannabis use may actually decrease the risk for cancer by 10%. “Decreased cancer risk in cannabis users should not be surprising, as cannabis and cannabinoids decrease obesity, inhibit chronic inflammation, reduce fasting insulin levels and insulin sensitivity, and have direct antitumor actions,” Clark writes.
Conclusion
Cannabis is simply much more effective than pharmaceutical drugs because the compounds in the plant bind to our very own endocannabinoid system to provide holistic healing. Using cannabis as part of a healthy lifestyle not only aids in reducing stress and anxiety or helping us sleep better, but it also has long-term health benefits. Provided that one also lives a balanced lifestyle, exercises regularly, eats well, and avoids stress, the studies we have so far suggest that adding cannabis to your daily routine can help ward off deadly diseases such as cancer.
Education News
AIIMS Gorakhpur Reservation Controversy: FIR Alleges Fake OBC Certificate Used Despite ₹80 Lakh Income
A major controversy has emerged at AIIMS Gorakhpur after allegations surfaced that reservation benefits were misused to secure a postgraduate medical seat. A criminal case has been registered against former AIIMS Gorakhpur Executive Director Dr. G.K. Pal and his son, Dr. Oro Prakash Pal, over the alleged use of a forged Other Backward Class (OBC) Non-Creamy Layer certificate for admission to an MD course.
The case has triggered widespread debate within medical and administrative circles, raising serious questions about transparency and oversight in admissions to premier medical institutions.
FIR Filed on Court’s Direction
The First Information Report (FIR) was registered at the AIIMS police station following directions from Chief Judicial Magistrate Tvishi Srivastava. According to the complaint, the alleged offence took place on August 30, 2024, when forged documents were purportedly used to obtain an MD seat under the OBC reservation quota.
Sources indicate that the matter was subsequently brought to the attention of the Union Ministry of Health, prompting internal reviews and administrative action.
Alleged Income Far Above Eligibility Threshold
Central to the allegations is the claim that Dr. G.K. Pal and his wife Parvati Pal have a combined annual income exceeding ₹80 lakh. Under existing reservation rules, families with such income levels are not eligible for OBC Non-Creamy Layer benefits.
Following the emergence of the controversy, Dr. Pal was first removed from his position at AIIMS Gorakhpur and later relieved of responsibilities at AIIMS Patna. He is currently posted at JIPMER Puducherry. With the registration of the FIR, officials suggest that further legal and departmental action may follow, depending on the outcome of the investigation.
Complaint Highlights Systemic Concerns
The complaint was filed by Ashutosh Kumar Mishra, a resident of Divyanagar in the Cantonment area. He alleged that the events related to the case occurred between January and September 2024. The complainant argued that misuse of reservation provisions by individuals in senior positions undermines the integrity of public institutions and erodes trust in the medical education system.
The case has reignited concerns over whether verification mechanisms for reservation certificates are robust enough, particularly in high-stakes admissions.
Impact on Medical Community
The allegations have sent shockwaves through the medical fraternity. Experts believe that if the claims are substantiated, the case could prompt a broader review of admission procedures and lead to stricter scrutiny of category certificates across institutions like AIIMS.
Authorities have stated that all relevant documents will be carefully examined before taking further steps. The outcome of the investigation is expected to have far-reaching implications for accountability and compliance in medical admissions.
Questions Await Answers
As the probe continues, several key issues remain unresolved: whether reservation norms were deliberately violated, how verification processes failed, and whether similar cases may surface in the future. For now, the focus remains on the investigation and its potential consequences.
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business2 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business2 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business2 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business2 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business2 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business2 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business2 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy